Primary central nervous system lymphoma

Current Treatment Options in Neurology

Volumn 8, Issue 4, 2006, Pages 346-357

  Pels, Hendrik ^b   Schlegel, Uwe ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; HYDROCORTISONE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TENIPOSIDE; THIOTEPA; TOSITUMOMAB I 131; TROFOSFAMIDE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAIN LYMPHOMA; BRAIN VENTRICULITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CATARACT; CLINICAL TRIAL; COGNITIVE DEFECT; CORNEA DISEASE; CORNEA EPITHELIUM; DIETARY INTAKE; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EYE CANCER; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIFESTYLE; LONG TERM CARE; MENINGITIS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; RETINA MACULOPATHY; REVIEW; STEREOTAXIC SURGERY; THROMBOCYTOPENIA;

EID: 33745386412     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-006-0024-8     Document Type: Review

References (62)

1. Schlegel U, Schmidt-Wolf IGH, Deckert M: Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000, 181:1-12.
2. Central Brain Tumor Registry of the United States, Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Chicago, IL: Central Brain Tumor Registry of the United States; 2005.
3. Sacktor N, Lyles RH, Skolasky R, et al.: HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001, 56:257-260.
4. Ferreri AJ, Blay JY, Reni M, et al.: Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 2002, 13:531-538.
5. Abrey LE, Batchelor TT, Ferreri AJM et al.: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005, 23:5034-5043.
6. Küker W, Nägele T, Korfel A, et al.: Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005, 72:169-177.
7. Gleissner B, Siehl J, Korfel A, et al.: CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002, 58:390-396.
8. Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J 2000, 1:53-66.
9. Shenkier TN, Blay JY, O'Neill BP, et al.: Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005, 23:2233-2239.
10. Jahnke K, Thiel E, Schilling A, et al.: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol 2005, 128:616-624.
11. Montesinos-Rongen M, Kuppers R, Schluter D, et al.: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999, 155:2077-2086.
12. Camilleri-Broet S, Criniere E, Broet P, et al.: A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006, 107:190-196.
13. Braaten KM, Betensky RA, de Leval L, et al.: BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003, 9:1063-1069.
14. Montesinos-Rongen M, Van Roost D, Schaller C, et al.: Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004, 103:1869-1875.
15. Nakamura M, Kishi M, Sakaki T, et al.: Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003, 63:737-741.
16. Weber T, Weber RG, Kaulich K, et al.: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000, 10:73-84.
17. Bellinzona M, Roser F, Ostertag H, et al.: Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005, 31:100-105.
18. Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23:9-17.
19. Shibamoto Y, Ogino H, Hasegawa M, et al.: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 2005, 62:809-813.
20. Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999, 43:241-247.
21. Ferreri AJ, Reni M, Pasini F, et al.: A multicenter study of treatment of primary CNS lymphoma. Neurology 2002, 58:1513-1520.
22. Herrlinger U, Küker W, Uhl M, et al.: NOA-03 multicenter trial of high-dose methotrexate therapy in primary CNS lymphoma: final report. Ann Neurol 2005, 57:843-847.
23. Batchelor T, Carson K, O'Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044-1049.
24. Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726-2731.
25. Pels H, Schmidt-Wolf IG, Glasmacher A, et al.: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003, 21:4489-4495.
26. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. Clin Oncol 2000, 18:3144-3150
27. DeAngelis LM, Seiferheld W, Schold SC, et al.: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002, 20:4643-4648.
28. Khan RB, Shi W, Thaler HT, et al.: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002, 58:175-178.
29. Soussain C, Hoang-Xuan K, Levy V: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Bull Cancer 2004, 91:189-192.
30. Abrey LE, Moskowitz CH, Mason WP, et al.: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003, 21:4151-4156.
31. Cheng T, Forsyth P, Chaudhry A, et al.: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003, 31:679-685.
32. Illerhaus G, Marks R, Derigs G, et al.: Primary CNS lymphoma: results of a multicenter phase II study including high-dose chemotherapy with autologous PBSCT and hyperfractionated radiotherapy as first-line-therapy. Ann Oncol 2005, 16(Suppl 5):v125.
33. Jahnke K, Korfel A, Martus P, et al.: High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005, 16:445-449.
34. Blay JY, Conroy T, Chevreau C, et al.: High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998, 16:864-871.
35. O'Brien P, Roos D, Pratt G, et al.: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000, 18:519-526.
36. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al.: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21:4483-4488.
37. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859-863.
38. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM: Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004, 62:451-456.
39. Fliessbach K, Helmstaedter C, Urbach H, et al.: Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005, 64:1184-1188.
40. Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62:548-555.
41. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005, 26:258-265.
42. Omuro AM, Ben-Porat LS, Panageas KS, et al.: Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005, 62:1595-1600.
43. Harder H, Holtel H, Bromberg JE, et al.: Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62:544-547.
44. Fisher B, Seiferheld W, Schultz C, et al.: Secondary analysis of Radiation Therapy Oncology Group (RTOG) study 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 2005, 74:201-205.
45. O'Brien PC, Roos DE, Pratt G, et al.: Combined-modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006, 64:408-413.
46. Herrlinger U, Küker W, Platten M, et al.: First-line therapy with temozolomide induces complete response in primary CNS lymphoma. Neurology 2002, 58:1573-1574.
47. Reni M, Mason W, Zaja F, et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004, 40:1682-1688.
48. Antinori A, Cingolani A, Alba L, et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15:1483-1491.
49. Hoffmann C, Tabrizian S, Wolf E, et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001, 15:2119-2127.
50. Jahnke K, Korfel A, Komm J, et al.: Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 2006, In press.
51. Smith JR, Rosenbaum JT, Wilson DJ, et al.: Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002, 109:1709-1716.
52. Reni M, Ferreri AJ: Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001, 80(Suppl 3):B113-B117.
53. Plotkin SR, Betensky RA, Hochberg FH, et al.: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004, 10:5643-5646.
54. Reni M, Mason W, Zaja F, et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004, 40:1682-1688.
55. Enting RH, Demopoulos A, DeAngelis LM, et al.: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004, 63:901-903.
56. Fischer L, Thiel E, Klasen HA, et al.: Response of relapsed or refractory primary CNS lymphoma (PCNSL) to topotecan. Neurology 2004, 62:1885-1887.
57. Nguyen PL, Chakravarti A, Finkelstein DM, et al.: Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005, 23:1507-1513.
58. Küker W, Nägele T, Thiel E, et al.: Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 2005, 65:1129-1131.
59. Palmedo H, Urbach H, Bender H, et al.: FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006, 33:164-168.
60. Panageas KS, Elkin EB, DeAngelis LM, et al.: Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 2005, 104:2466-2472.
61. Wong ET: Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert Opin Pharmacother 2005, 6:1107-1114.
62. Pels H, Schulz H, Schlegel U, Engert A: Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003, 26:351-354.